Osteosarcoma is kind of bone tumour in which there is multiplication of osteoblasts. The tumour is basic kind of malignant growth encouraging the growth of the immature bones. The tumour is typically seen in both children and adolescents. The disease is more prevalent in the males than females. Intramedullary osteosarcoma, extraskeletal osteosarcoma and Juxtacortical osteosarcoma, are three types of osteosarcomas, out of which intramedullary osteosarcoma is most predominant one.
Growing prevalence of the disease among the children and the teenagers along with rising demand for better treatment advantages are one of key drivers responsible for growth of the global market over the forecast period.Segment Overview
The incidences of disease are on steady rise and need to be addressed at the earliest, to reduce the burden of osteosarcoma across the world.
According to American Society of Clinical Oncology (ASCO), the U.S. was expected to observe 3,450 new cases of the bone cancer, and an anticipated 1,590 deaths due to the disease in 2018.
Moreover, it is vital to assure timely treatment and diagnosis, in order to increase survival rate. Many government societies are taking initiatives to create and increase awareness about the bone cancer. For instance, UK Government formed organization named Genomics England, post launch of 100,000 Genomes Project in the year 2012. The organization is responsible for the sequencing of almost 100,000 genomes from the 700,000 genomes of the NHS-registered patients.Regional Overview
North America presently dominates the market, and it is anticipated to continue its position during the forecast period. The region is anticipated to increase its share in the coming future, owing to fact that, currently, many clinical trials are on-going for various bone cancer therapies in the U.S. Some studies are testing novel chemo drugs. Researchers are looking for various new ways to use existing approved drug portfolio. For instance, the doctors are reviewing whether adding bisphosphonate called zoledronic acid to the bone cement, that is used in filling space left after eliminating a giant cell tumour, may decrease chances of that tumour returning in that place.Competitor overview
The global market is highly competitive and is consists of considerable number of noteworthy players. All of existing players in the global market are either legacy suppliers of the treatment options, such as chemo and radiation therapy, or are focused on the clinical trials for novel approaches, including immunotherapy and targeted therapy. Companies, such as Bayer AG, Novartis AG, Amgen, and Pfizer Inc., among others, are anticipated to hold substantial market share in market.
Various developments have lately been taking place in market. For instance, September 2016, Dr. Reddy's Laboratories expanded strategic alliance with Amgen to distribute and market Vectibix (panitumumab), Xgeva (denosumab), and Prolia (denosumab) in India.Key Players
- Bayer AG
- Hikma Pharmaceuticals
- Johnson & Johnson
- Novartis AG
- Pfizer Inc.
- Recordati Group
- Takeda Pharmaceutical Company
- Targeted Drug Therapy
- Radiation Therapy
By End User
- Specialty Clinics
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- Rest of LAMEA